Showing 1 - 20 results of 20 for search 'Jasper Dingemanse', query time: 0.08s Refine Results
  1. 1
    Drug Development for Pediatric Populations: Regulatory Aspects

    Drug Development for Pediatric Populations: Regulatory Aspects by Jochen Zisowsky, Jasper Dingemanse, Andreas Krause

    Published 2010-11-01
    Get full text
    Article
  2. 2
    Clinical Pharmacology of Clazosentan, a Selective Endothelin A Receptor Antagonist for the Prevention and Treatment of aSAH-Related Cerebral Vasospasm

    Clinical Pharmacology of Clazosentan, a Selective Endothelin A Receptor Antagonist for the Prevention and Treatment of aSAH-Related Cerebral Vasospasm by Pierre-Eric Juif, Jasper Dingemanse, Mike Ufer

    Published 2021-02-01
    Get full text
    Article
  3. 3
    Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y12 receptor between selatogrel and oral P2Y12 antagonists

    Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y12 receptor between selatogrel and oral P2Y12 antagonists by Andrea Henrich, Christian Hove Claussen, Jasper Dingemanse, Andreas Krause

    Published 2021-07-01
    Get full text
    Article
  4. 4
    Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects

    Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects by Isabelle Zenklusen, Jasper Dingemanse, Christian Reh, Martine Gehin, Priska Kaufmann

    Published 2024-03-01
    Get full text
    Article
  5. 5
    Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist

    Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist by Andreas Krause, Dominik Lott, Janneke M. Brussee, Clemens Muehlan, Jasper Dingemanse

    Published 2023-01-01
    Get full text
    Article
  6. 6
    Influence of Rifampin‐Mediated Organic Anion‐Transporting Polypeptide 1B1/1B3 Inhibition on the Pharmacokinetics of Clazosentan

    Influence of Rifampin‐Mediated Organic Anion‐Transporting Polypeptide 1B1/1B3 Inhibition on the Pharmacokinetics of Clazosentan by Pierre‐Eric Juif, Christine Voors‐Pette, Mike Ufer, Peter Dogterom, Jasper Dingemanse

    Published 2019-09-01
    Get full text
    Article
  7. 7
    Effect of nivasorexant (ACT‐539313), a selective orexin‐1‐receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects

    Effect of nivasorexant (ACT‐539313), a selective orexin‐1‐receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in health... by Benjamin Berger, Priska Kaufmann, Matthias Berse, Alexander Treiber, Nathalie Grignaschi, Jasper Dingemanse

    Published 2023-10-01
    Get full text
    Article
  8. 8
    Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment

    Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment by Magda S. C. Fontes, Jasper Dingemanse, Atef Halabi, Monika Tomaszewska-Kiecana, Patricia N. Sidharta

    Published 2022-11-01
    Get full text
    Article
  9. 9
    Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor Antagonists

    Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor Antagonists by Chih-hsuan Hsin, Jasper Dingemanse, Andrea Henrich, Corine Bernaud, Martine Gehin, Andreas Krause

    Published 2023-09-01
    Get full text
    Article
  10. 10
    Effect of Rifampin‐Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel

    Effect of Rifampin‐Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel by Uta Schilling, Jasper Dingemanse, Christine Voors‐Pette, Christel Romeijn, Peter Dogterom, Mike Ufer

    Published 2020-09-01
    Get full text
    Article
  11. 11
    Assessment of Target Engagement in a First‐in‐Human Trial with Sinbaglustat, an Iminosugar to Treat Lysosomal Storage Disorders

    Assessment of Target Engagement in a First‐in‐Human Trial with Sinbaglustat, an Iminosugar to Treat Lysosomal Storage Disorders by Martine Gehin, Meggane Melchior, Richard W.D. Welford, Patricia N. Sidharta, Jasper Dingemanse

    Published 2021-03-01
    Get full text
    Article
  12. 12
    The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first‐in‐class ACKR3/CXCR7 antagonist, ACT‐1004‐1239

    The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first‐in‐class ACKR3/CXCR7 antagonist, ACT‐1004‐1239 by Christine Huynh, Jasper Dingemanse, Henriette E. Meyer zu Schwabedissen, Marlene Fonseca, Patricia N. Sidharta

    Published 2024-07-01
    Get full text
    Article
  13. 13
    The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects

    The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects by Markus S. Mueller, Patricia N. Sidharta, Christine Voors-Pette, Borje Darpo, Hongqi Xue, Jasper Dingemanse

    Published 2020-10-01
    Get full text
    Article
  14. 14
    Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel

    Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel by Uta Schilling, Chih‐Hsuan Hsin, Stephane Delahaye, Andreas Krause, Hauke Wuelfrath, Atef Halabi, Jasper Dingemanse

    Published 2022-08-01
    Get full text
    Article
  15. 15
    Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT‐1014‐6470 in vitro and in vivo

    Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT‐1014‐6470 in vitro and in vivo by Marion Anliker‐Ort, Jasper Dingemanse, Stephane Delahaye, Luboš Janů, John van denAnker, Benjamin Berger, Priska Kaufmann

    Published 2023-07-01
    Get full text
    Article
  16. 16
    Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway

    Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway by Marion Anliker-Ort, Marion Anliker-Ort, Jasper Dingemanse, John van den Anker, John van den Anker, Priska Kaufmann

    Published 2020-12-01
    Get full text
    Article
  17. 17
    Modeling time‐delayed concentration‐QT effects with ACT‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5a1 receptor) antagonist

    Modeling time‐delayed concentration‐QT effects with ACT‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5a1 receptor) antagonist by Marion Anliker‐Ort, Chih‐hsuan Hsin, Andreas Krause, Marc Pfister, John van denAnker, Jasper Dingemanse, Priska Kaufmann

    Published 2023-08-01
    Get full text
    Article
  18. 18
    Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: In Vitro, Preclinical, and Clinical Data

    Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: In Vitro, Preclinical, and Clinical Data by Christine Huynh, Christine Huynh, Swen Seeland, Jerome Segrestaa, Carmela Gnerre, Jens Hogeback, Henriette E. Meyer zu Schwabedissen, Jasper Dingemanse, Patricia N. Sidharta

    Published 2022-03-01
    Get full text
    Article
  19. 19
    The interactive walkway provides fit‐for‐purpose fall‐risk biomarkers in the elderly: Comparison of zolpidem and suvorexant

    The interactive walkway provides fit‐for‐purpose fall‐risk biomarkers in the elderly: Comparison of zolpidem and suvorexant by Ingrid Koopmans, Daphne Geerse, Lara deRidder, Melvyn Roerdink, Maria Joanna Juachon, Clemens Muehlan, Jasper Dingemanse, Joop vanGerven, Geert Jan Groeneveld, Rob Zuiker

    Published 2024-07-01
    Get full text
    Article
  20. 20
    Quantification of increased biologically active CXCL12α plasma concentrations after ACKR3 antagonist treatment in humans

    Quantification of increased biologically active CXCL12α plasma concentrations after ACKR3 antagonist treatment in humans by Peter Blattmann, Hervé Farine, Brian Dan, Nicole Stiffler, Thomas Lefebvre, Christine Huynh, Patricia N. Sidharta, Jasper Dingemanse, Richard W. D. Welford, Marcel Keller, Daniel S. Strasser

    Published 2024-02-01
    Get full text
    Article

Search Tools: